Hepatic inflammatory responses in liver fibrosis

L Hammerich, F Tacke - Nature Reviews Gastroenterology & …, 2023 - nature.com
Chronic liver diseases such as nonalcoholic fatty liver disease (NAFLD) or viral hepatitis are
characterized by persistent inflammation and subsequent liver fibrosis. Liver fibrosis critically …

Obesity in adults

I Lingvay, RV Cohen, CW le Roux, P Sumithran - The Lancet, 2024 - thelancet.com
Obesity has increased in prevalence worldwide and WHO has declared it a global epidemic.
Population-level preventive interventions have been insufficient to slow down this trajectory …

EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD)

European Association for the Study of the Liver (EASL)… - Obesity Facts, 2024 - karger.com
Metabolic dysfunction-associated steatotic liver disease (MASLD), previously termed non-
alcoholic fatty liver disease (NAFLD), is defined as steatotic liver disease (SLD) in the …

Steatotic liver disease: pathophysiology and emerging pharmacotherapies

M Kokkorakis, E Muzurović, Š Volčanšek… - Pharmacological …, 2024 - Elsevier
Steatotic liver disease (SLD) displays a dynamic and complex disease phenotype.
Consequently, the metabolic dysfunction-associated steatotic liver disease …

Obesity and cardiovascular disease: an ESC clinical consensus statement

KC Koskinas, EM Van Craenenbroeck… - European Heart …, 2024 - academic.oup.com
The global prevalence of obesity has more than doubled over the past four decades,
currently affecting more than a billion individuals. Beyond its recognition as a high-risk …

Prevention of cardiorenal complications in people with type 2 diabetes and obesity

DJ Drucker - Cell Metabolism, 2024 - cell.com
Traditional approaches to prevention of the complications of type 2 diabetes (T2D) and
obesity have focused on reduction of blood glucose and body weight. The development of …

Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes …

M Kouvari, L Valenzuela-Vallejo, V Guatibonza-Garcia… - Metabolism, 2023 - Elsevier
Background Non-invasive tools (NIT) for metabolic-dysfunction associated liver disease
(MASLD) screening or diagnosis need to be thoroughly validated using liver biopsies …

[HTML][HTML] Obesity and its comorbidities, current treatment options and future perspectives: Challenging bariatric surgery?

S Kloock, CG Ziegler, U Dischinger - Pharmacology & Therapeutics, 2023 - Elsevier
Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease,
heart failure and non-alcoholic liver disease are a major health and economic burden with …

Natural history and progression of metabolic dysfunction-associated steatotic liver disease

H Hagström, Y Shang, H Hegmar… - … Lancet Gastroenterology & …, 2024 - thelancet.com
The natural history of metabolic dysfunction-associated steatotic liver disease (MASLD),
previously referred to as non-alcoholic fatty liver disease (NAFLD), is complex and long. A …

Towards precision medicine in non-alcoholic fatty liver disease

SM Francque - Reviews in Endocrine and Metabolic Disorders, 2023 - Springer
Abstract Non-Alcoholic Fatty Liver Disease (NAFLD) refers to the accumulation of lipid laden
vacuoles in hepatocytes, occurring in the context of visceral adiposity, insulin resistance and …